Dyspepsia Market Report and Forecast 2025-2034
Description
The dyspepsia market size was valued at USD 1102.40 Million in 2024, driven by the rising advancements in medical research and development activities across the 7 major markets. The market is expected to grow at a CAGR of 8.40% during the forecast period of 2025-2034, with the value likely to rise to USD 2469.63 Million by 2034.
Dyspepsia: Introduction
Dyspepsia, also known as indigestion, is characterized by stomach pain, bloating, and fullness during or after eating. Other symptoms include heartburn, acid reflux, and excessive burping. There are different categories of functional dyspepsia, which involve epigastric pain syndrome as well as postprandial distress syndrome. It may be caused by food allergies, visceral hypersensitivity, and H. pylori infection.
Dyspepsia Market Analysis
The market growth is driven by the high prevalence of the disease worldwide. The incidence is particularly higher in the western countries, affecting 10% to 40% of the population, while the Asian countries have a prevalence rate of 5% to 30%. Diagnostic tests play a pivot role in offering early treatment, hence, upper endoscopy, breath tests and gastric emptying studies are also used for precise diagnosis.
The increased availability of treatment and drugs in the market are also aiding the dyspepsia market growth. Dyspepsia is treated via medication that works to reduce acid production and block acid pumps. Others may include antibiotics to fight against H. pylori bacteria and prokinetics that tighten the valves between stomach and esophagus, helping in abdominal pain reduction.
Apart from pharmacological interventions, herbal and traditional medicinal approaches are another area of interest amongst researchers. Herbals such as peppermint, caraway oil, and turmeric are heavily investigated and have displayed positive results in patients when compared to regular placebos. This is also indicative of the general market trend of adopting wellness and natural products in combination with pharmaceuticals for disease treatments.
Dyspepsia Market Segmentation
Dyspepsia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Diagnosis Germany
France
Italy
Spain
United Kingdom
In the forecast period, the United States is expected to lead the dyspepsia market share. With proactive healthcare and research institutions, there is a heavy emphasis on educating the masses about the condition through early diagnosis and appropriate treatment. In addition, the booming pharmaceutical sector is working on bringing in effective and innovative solutions for patients.
Europe is another major player in the market with a robust healthcare infrastructure, along with rising collaborations between academic and research organizations to develop alternative therapeutics for people. The substantial portion of geriatric population pertaining to the region is another key aspect of the considerable market share of the condition.
The dyspepsia market value is projected to grow with the increasing utility of naturopathy and rising adoption of traditional eastern medicine alternatives for treating the condition. Moreover, the region is witnessing impressive improvements in the medical and research infrastructure which is fostering market growth. Increased influx of foreign capital is another major factor.
Dyspepsia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Dyspepsia: Introduction
Dyspepsia, also known as indigestion, is characterized by stomach pain, bloating, and fullness during or after eating. Other symptoms include heartburn, acid reflux, and excessive burping. There are different categories of functional dyspepsia, which involve epigastric pain syndrome as well as postprandial distress syndrome. It may be caused by food allergies, visceral hypersensitivity, and H. pylori infection.
Dyspepsia Market Analysis
The market growth is driven by the high prevalence of the disease worldwide. The incidence is particularly higher in the western countries, affecting 10% to 40% of the population, while the Asian countries have a prevalence rate of 5% to 30%. Diagnostic tests play a pivot role in offering early treatment, hence, upper endoscopy, breath tests and gastric emptying studies are also used for precise diagnosis.
The increased availability of treatment and drugs in the market are also aiding the dyspepsia market growth. Dyspepsia is treated via medication that works to reduce acid production and block acid pumps. Others may include antibiotics to fight against H. pylori bacteria and prokinetics that tighten the valves between stomach and esophagus, helping in abdominal pain reduction.
Apart from pharmacological interventions, herbal and traditional medicinal approaches are another area of interest amongst researchers. Herbals such as peppermint, caraway oil, and turmeric are heavily investigated and have displayed positive results in patients when compared to regular placebos. This is also indicative of the general market trend of adopting wellness and natural products in combination with pharmaceuticals for disease treatments.
Dyspepsia Market Segmentation
Dyspepsia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Diagnosis
- Blood Tests
- Stool Tests
- Breath Tests
- Endoscopy
- X-Ray
- CT Scan
- Others
- Organic Dyspepsia
- Non-Ulcer Dyspepsia
- Drug Induced Dyspepsia
- Others
- Functional Dyspepsia
- Organic Dyspepsia
- Proton Pump Inhibitors
- H2 Blockers
- Antacids
- Antibiotics
- Prokinetics
- Antidepressants
- Medication
- Surgery
- Branded
- Generic
- Oral
- Injectable
- United States
- EU-4 and the United Kingdom
- Japan
In the forecast period, the United States is expected to lead the dyspepsia market share. With proactive healthcare and research institutions, there is a heavy emphasis on educating the masses about the condition through early diagnosis and appropriate treatment. In addition, the booming pharmaceutical sector is working on bringing in effective and innovative solutions for patients.
Europe is another major player in the market with a robust healthcare infrastructure, along with rising collaborations between academic and research organizations to develop alternative therapeutics for people. The substantial portion of geriatric population pertaining to the region is another key aspect of the considerable market share of the condition.
The dyspepsia market value is projected to grow with the increasing utility of naturopathy and rising adoption of traditional eastern medicine alternatives for treating the condition. Moreover, the region is witnessing impressive improvements in the medical and research infrastructure which is fostering market growth. Increased influx of foreign capital is another major factor.
Dyspepsia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bayer AG
- Mankind Pharma
- Cadila Pharmaceuticals
- Salix Pharmaceuticals
- Sanofi
- Aosaikand Pharmaceutical Co., Ltd
- Hanmi Pharm. Co.
- Lupin
- RedHill Biopharma Ltd.
- Abbott.
- GlaxoSmithKline
- Johnson&Johnson
- Eisai Co Ltd
- AstraZeneca
- Allergen Plc
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Dyspepsia Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Drug
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Dyspepsia Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Dyspepsia Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Dyspepsia Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Dyspepsia Epidemiology Forecast (2018-2034)
- 5.3.2 France Dyspepsia Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Dyspepsia Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Dyspepsia Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Dyspepsia Epidemiology Forecast (2018-2034)
- 5.4 Japan Dyspepsia Epidemiology Forecast (2018-2034)
- 6 Dyspepsia Market Overview – 7MM
- 6.1 Dyspepsia Market Historical Value (2018-2024)
- 6.2 Dyspepsia Market Forecast Value (2025-2034)
- 7 Dyspepsia Market Landscape – 7MM
- 7.1 Dyspepsia: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Dyspepsia Product Landscape
- 7.2.1 Analysis by Indication
- 7.2.2 Analysis by Drug Type
- 8 Dyspepsia Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Dyspepsia Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Dyspepsia Market Segmentation – 7MM
- 11.1 Dyspepsia Market by Diagnosis
- 11.1.1 Market Overview
- 11.1.2 Blood Tests
- 11.1.3 Stool Tests
- 11.1.4 Breath Tests
- 11.1.5 Endoscopy
- 11.1.6 X-Ray
- 11.1.7 CT Scan
- 11.1.8 Others
- 11.2 Dyspepsia Market by Type
- 11.2.1 Market Overview
- 11.2.2 Organic Dyspepsia
- 11.2.3 Non-Ulcer Dyspepsia
- 11.2.4 Drug Induced Dyspepsia
- 11.2.5 Others
- 11.3 Dyspepsia Market by Indication
- 11.3.1 Market Overview
- 11.3.2 Functional Dyspepsia
- 11.3.3 Organic Dyspepsia
- 11.4 Dyspepsia Market by Treatment
- 11.4.1 Market Overview
- 11.4.2 Proton Pump Inhibitors
- 11.4.3 H2 Blockers
- 11.4.4 Antacids
- 11.4.5 Antibiotics
- 11.4.6 Prokinetics
- 11.4.7 Antidepressants
- 11.5 Dyspepsia Market by Treatment Type
- 11.5.1 Market Overview
- 11.5.2 Medication
- 11.5.3 Surgery
- 11.6 Dyspepsia Market by Drug Type
- 11.6.1 Market Overview
- 11.6.2 Branded
- 11.6.3 Generic
- 11.7 Dyspepsia Market by Route of Administration
- 11.7.1 Market Overview
- 11.7.2 Oral
- 11.7.3 Injectable
- 11.8 Dyspepsia Market by Region
- 11.8.1 Market Overview
- 11.8.2 United States
- 11.8.3 EU-4 and the United Kingdom
- 11.8.3.1 Germany
- 11.8.3.2 France
- 11.8.3.3 Italy
- 11.8.3.4 Spain
- 11.8.3.5 United Kingdom
- 11.8.4 Japan
- 12 United States Dyspepsia Market
- 12.1 Dyspepsia Market Historical Value (2018-2024)
- 12.2 Dyspepsia Market Forecast Value (2025-2034)
- 12.3 Dyspepsia Market by Diagnosis
- 12.4 Dyspepsia Market by Indication
- 13 EU-4 and United Kingdom Dyspepsia Market
- 13.1 Dyspepsia Market Historical Value (2018-2024)
- 13.2 Dyspepsia Market Forecast Value (2025-2034)
- 13.3 Germany Dyspepsia Market Overview
- 13.3.1 Dyspepsia Market by Diagnosis
- 13.3.2 Dyspepsia Market by Indication
- 13.4 France Dyspepsia Market Overview
- 13.4.1 Dyspepsia Market by Diagnosis
- 13.4.2 Dyspepsia Market by Indication
- 13.5 Italy Dyspepsia Market Overview
- 13.5.1 Dyspepsia Market by Diagnosis
- 13.5.2 Dyspepsia Market by Indication
- 13.6 Spain Dyspepsia Market Overview
- 13.6.1 Dyspepsia Market by Diagnosis
- 13.6.2 Dyspepsia Market by Indication
- 13.7 United Kingdom Dyspepsia Market Overview
- 13.7.1 Dyspepsia Market by Diagnosis
- 13.7.2 Dyspepsia Market by Indication
- 14 Japan Dyspepsia Market
- 14.1 Dyspepsia Market Historical Value (2018-2024)
- 14.2 Dyspepsia Market Forecast Value (2025-2034)
- 14.3 Dyspepsia Market by Diagnosis
- 14.4 Dyspepsia Market by Indication
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Bayer AG
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Mankind Pharma
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Cadila Pharmaceuticals
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Salix Pharmaceuticals
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Sanofi
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Aosaikand Pharmaceutical Co., Ltd
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Hanmi Pharm. Co.
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Lupin
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 RedHill Biopharma Ltd.
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Abbott.
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 GlaxoSmithKline
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 Johnson & Johnson
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Eisai Co Ltd
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 AstraZeneca
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 Allergen Plc
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 22 Dyspepsia Market- Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
